Tumor Targeted Alpha Particle Therapy with an Actinium-225 Labelled Antibody for Carbonic Anhydrase IX

Katherine Anne Morgan,Christian Wichmann,Laura Ossellame,Zhipeng Cao,Nancy Guo,Andrew Scott,Paul Stephen Donnelly
DOI: https://doi.org/10.1039/d3sc06365h
IF: 8.4
2024-01-26
Chemical Science
Abstract:Selective antibody targeted delivery of ⍺ particle emitting actinium-225 to tumors has significant therapeutic potential. This work highlights the design and synthesis of a new bifunctional macrocyclic diazacrown ether chelator, H2MacropaSqOEt, that can be conjugated to antibodies and forms stable complexes with actinium-225. The macrocyclic diazacrown ether chelator incorporates a linker comprised of a short polyethylene glycol fragment and a squaramide ester that allows selective reaction with lysine residues on antibodies to form stable vinylogous amide linkages. This new H2MacropaSqOEt chelator was used to modify a monoclonal antibody, girentuximab (hG250), that binds to carbonic anhydrase IX, an enzyme that is overexpressed on the surface of cancers such as clear cell renal cell carcinoma. This new antibody conjugate (H2MacropaSq-hG250) had an average chelator to antibody ratio of 4:1 and retained high affinity for carbonic anhydrase IX. H2MacropaSq-hG250 was radiolabeled quantitatively with [225Ac]AcIII within one minute at room temperature with micromolar concentrations of antibody and the radioactive complex is stable in human serum for > 7 days. Evaluation of [225Ac]Ac(MacropaSq-hG250) in a mouse xenograft model, that overexpresses carbonic anhydrase IX, demonstrated a highly significant therapeutic response. It is likely that H2MacropaSqOEt could be used to modify other antibodies providing a readily adaptable platform for other actinium-225 based therapeutics.
chemistry, multidisciplinary
What problem does this paper attempt to address?
The problem that this paper attempts to solve is to develop a new radionuclide therapy targeting tumors, especially those tumors expressing carbonic anhydrase IX (CAIX). Specifically, the researchers designed and synthesized a new bifunctional macrocyclic diaza - crown - ether chelator H₂MacropaSqOEt and conjugated it with the monoclonal antibody girentuximab (hG250) to achieve selective delivery to tumor cells. By binding to the alpha - particle emitter actinium - 225 (²²⁵Ac), this study aims to improve the treatment effect on hypoxic tumors. ### Research Background and Problem Description 1. **Challenges in Cancer Treatment**: - Traditional radiotherapy and chemotherapy have limited effectiveness in treating certain types of cancer, especially for hypoxic tumors. Due to insufficient oxygen supply, these tumors have poor efficacy with traditional beta - particle radionuclides. - Alpha - particle emitters such as ²²⁵Ac have high linear energy transfer (LET) and can effectively kill cancer cells in a low - oxygen environment, but they require highly efficient and stable chelators to ensure effective binding and delivery with antibodies. 2. **Limitations of Existing Technologies**: - Previous studies have mainly focused on beta - particle radionuclides, such as ¹⁷⁷Lu, but their efficacy in a hypoxic environment is limited. - Commonly used chelators such as DOTA have stability problems when binding to ²²⁵Ac. They require high - temperature reactions and long reaction times, which may lead to antibody denaturation or low labeling efficiency. 3. **Research Objectives**: - Develop a new type of chelator H₂MacropaSqOEt that can quickly and stably bind to ²²⁵Ac and complete the labeling in a short time at room temperature. - Conjugate this chelator with the monoclonal antibody girentuximab (hG250), which specifically recognizes CAIX, to form an immunoconjugate for targeted delivery of ²²⁵Ac to tumor cells overexpressing CAIX. - Verify the stability and treatment effect of this immunoconjugate in in - vivo and in - vitro experiments. ### Key Innovation Points - **Design of a New Chelator**: H₂MacropaSqOEt improves water solubility and stability by introducing a squaramide ethyl ester functional group, avoiding the problem of easy hydrolysis of the isothiocyanate functional group. - **Fast and Efficient Labeling Method**: H₂MacropaSqOEt can quantitatively label ²²⁵Ac within a few minutes at room temperature, significantly improving the labeling efficiency and the antibody activity retention rate. - **In - vivo Experiment Verification**: In the SK - RC - 52 mouse xenograft tumor model, [²²⁵Ac]Ac(MacropaSq - hG250) shows a significant treatment effect, prolongs the survival period, and induces DNA double - strand breaks in tumor tissues. ### Summary This study successfully developed a new chelator H₂MacropaSqOEt and applied it to the targeted delivery of ²²⁵Ac, providing a potentially effective means for treating hypoxic tumors. By optimizing the synthesis method and labeling conditions, the researchers achieved the preparation of highly efficient and stable immunoconjugates and verified their good treatment effects in animal experiments. This lays the foundation for the future development of more ²²⁵Ac - based radioimmunotherapies.